1
|
Journeaux T, Bernardes GJL. Homogeneous multi-payload antibody-drug conjugates. Nat Chem 2024; 16:854-870. [PMID: 38760431 DOI: 10.1038/s41557-024-01507-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 03/14/2024] [Indexed: 05/19/2024]
Abstract
Many systemic cancer chemotherapies comprise a combination of drugs, yet all clinically used antibody-drug conjugates (ADCs) contain a single-drug payload. These combination regimens improve treatment outcomes by producing synergistic anticancer effects and slowing the development of drug-resistant cell populations. In an attempt to replicate these regimens and improve the efficacy of targeted therapy, the field of ADCs has moved towards developing techniques that allow for multiple unique payloads to be attached to a single antibody molecule with high homogeneity. However, the methods for generating such constructs-homogeneous multi-payload ADCs-are both numerous and complex owing to the plethora of reactive functional groups that make up the surface of an antibody. Here, by summarizing and comparing the methods of both single- and multi-payload ADC generation and their key preclinical and clinical results, we provide a timely overview of this relatively new area of research. The methods discussed range from branched linker installation to the incorporation of unnatural amino acids, with a generalized comparison tool of the most promising modification strategies also provided. Finally, the successes and challenges of this rapidly growing field are critically evaluated, and from this, future areas of research and development are proposed.
Collapse
Affiliation(s)
- Toby Journeaux
- Department of Chemistry, University of Cambridge, Cambridge, UK
| | - Gonçalo J L Bernardes
- Department of Chemistry, University of Cambridge, Cambridge, UK.
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
| |
Collapse
|
2
|
Patel M, Forte N, Bishop CR, Porter MJ, Dagwell M, Karu K, Chudasama V, Baker JR. The Nitrile Bis-Thiol Bioconjugation Reaction. J Am Chem Soc 2024; 146:274-280. [PMID: 38124442 PMCID: PMC10786040 DOI: 10.1021/jacs.3c08762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 12/01/2023] [Accepted: 12/04/2023] [Indexed: 12/23/2023]
Abstract
Electron-poor aryl nitriles are promising reagents for bioconjugation due to their high electrophilicity and selectivity for reaction with thiols, albeit generally in a reversible manner. A transient species has previously been observed in such reactions, involving the addition of two thiols to the nitrile functional group, forming a tetrahedral amino dithioacetal (ADTA). In this work, the reaction of heteroaryl nitriles with bis-thiols is explored in an attempt to generate stable ADTAs, which could facilitate new bioconjugation protocols. By use of a 1,2-dithiol, or the incorporation of an electrophilic trap into the aryl nitrile design, the formation of stable products is achieved. The resultant "nitrile bis-thiol" (NBT) reaction is then explored in the context of protein modification, specifically to carry out antibody conjugation. By addition of these nitriles to the reduced disulfide bond of an antibody fragment, it is shown that, depending on the reagent design, cysteine-to-lysine transfer or disulfide bridged NBT products can be generated. Both represent site-selective conjugates and are shown to be stable when challenged with glutathione under physiological conditions and upon incubation in serum. Furthermore, the NBT reaction is tested in the more challenging context of a full antibody, and all four disulfide bonds are effectively modified by these new one-carbon bridging reagents. Overall, this reaction of heteroaryl-nitriles with bis-thiols is shown to be highly efficient and versatile, of tunable reversibility, and offers enticing prospects as a new addition to the toolbox of biocompatible "click"-type reactions.
Collapse
Affiliation(s)
- Mikesh Patel
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| | - Nafsika Forte
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| | - Charlie R. Bishop
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| | - Michael J. Porter
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| | - Matthew Dagwell
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| | - Kersti Karu
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| | - Vijay Chudasama
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| | - James R. Baker
- Department
of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, U.K.
| |
Collapse
|
3
|
Chauhan P, V R, Kumar M, Molla R, Mishra SD, Basa S, Rai V. Chemical technology principles for selective bioconjugation of proteins and antibodies. Chem Soc Rev 2024; 53:380-449. [PMID: 38095227 DOI: 10.1039/d3cs00715d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Abstract
Proteins are multifunctional large organic compounds that constitute an essential component of a living system. Hence, control over their bioconjugation impacts science at the chemistry-biology-medicine interface. A chemical toolbox for their precision engineering can boost healthcare and open a gateway for directed or precision therapeutics. Such a chemical toolbox remained elusive for a long time due to the complexity presented by the large pool of functional groups. The precise single-site modification of a protein requires a method to address a combination of selectivity attributes. This review focuses on guiding principles that can segregate them to simplify the task for a chemical method. Such a disintegration systematically employs a multi-step chemical transformation to deconvolute the selectivity challenges. It constitutes a disintegrate (DIN) theory that offers additional control parameters for tuning precision in protein bioconjugation. This review outlines the selectivity hurdles faced by chemical methods. It elaborates on the developments in the perspective of DIN theory to demonstrate simultaneous regulation of reactivity, chemoselectivity, site-selectivity, modularity, residue specificity, and protein specificity. It discusses the progress of such methods to construct protein and antibody conjugates for biologics, including antibody-fluorophore and antibody-drug conjugates (AFCs and ADCs). It also briefs how this knowledge can assist in developing small molecule-based covalent inhibitors. In the process, it highlights an opportunity for hypothesis-driven routes to accelerate discoveries of selective methods and establish new targetome in the precision engineering of proteins and antibodies.
Collapse
Affiliation(s)
- Preeti Chauhan
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, 462 066, India.
| | - Ragendu V
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, 462 066, India.
| | - Mohan Kumar
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, 462 066, India.
| | - Rajib Molla
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, 462 066, India.
| | - Surya Dev Mishra
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, 462 066, India.
| | - Sneha Basa
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, 462 066, India.
| | - Vishal Rai
- Department of Chemistry, Indian Institute of Science Education and Research Bhopal, 462 066, India.
| |
Collapse
|
4
|
Rochet LNC, Bahou C, Wojciechowski JP, Koutsopetras I, Britton P, Spears RJ, Thanasi IA, Shao B, Zhong L, Bučar DK, Aliev AE, Porter MJ, Stevens MM, Baker JR, Chudasama V. Use of pyridazinediones for tuneable and reversible covalent cysteine modification applied to peptides, proteins and hydrogels. Chem Sci 2023; 14:13743-13754. [PMID: 38075666 PMCID: PMC10699563 DOI: 10.1039/d3sc04976k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 10/27/2023] [Indexed: 05/02/2024] Open
Abstract
Reversible cysteine modification has been found to be a useful tool for a plethora of applications such as selective enzymatic inhibition, activity-based protein profiling and/or cargo release from a protein or a material. However, only a limited number of reagents display reliable dynamic/reversible thiol modification and, in most cases, many of these reagents suffer from issues of stability, a lack of modularity and/or poor rate tunability. In this work, we demonstrate the potential of pyridazinediones as novel reversible and tuneable covalent cysteine modifiers. We show that the electrophilicity of pyridazinediones correlates to the rates of the Michael addition and retro-Michael deconjugation reactions, demonstrating that pyridazinediones provide an enticing platform for readily tuneable and reversible thiol addition/release. We explore the regioselectivity of the novel reaction and unveil the reason for the fundamental increased reactivity of aryl bearing pyridazinediones by using DFT calculations and corroborating findings with SCXRD. We also applied this fundamental discovery to making more rapid disulfide rebridging agents in related work. We finally provide the groundwork for potential applications in various areas with exemplification using readily functionalised "clickable" pyridazinediones on clinically relevant cysteine and disulfide conjugated proteins, as well as on a hydrogel material.
Collapse
Affiliation(s)
- Léa N C Rochet
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Calise Bahou
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Jonathan P Wojciechowski
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London London SW7 2AZ UK
| | - Ilias Koutsopetras
- Bio-Functional Chemistry (UMR 7199), Institut du Médicament de Strasbourg, University of Strasbourg 74 Route du Rhin 67400 Illkirch-Graffenstaden France
| | - Phyllida Britton
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Richard J Spears
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Ioanna A Thanasi
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Baihao Shao
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London London SW7 2AZ UK
| | - Lisha Zhong
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London London SW7 2AZ UK
| | - Dejan-Krešimir Bučar
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Abil E Aliev
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Michael J Porter
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Molly M Stevens
- Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London London SW7 2AZ UK
| | - James R Baker
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Vijay Chudasama
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| |
Collapse
|
5
|
Bahou C, Spears RJ, Ramírez Rosales AM, Rochet LNC, Barber LJ, Stankevich KS, Miranda JF, Butcher TC, Kerrigan AM, Lazarov VK, Grey W, Chudasama V, Spicer CD. Hydrogel Cross-Linking via Thiol-Reactive Pyridazinediones. Biomacromolecules 2023; 24:4646-4652. [PMID: 37792488 PMCID: PMC10646975 DOI: 10.1021/acs.biomac.3c00290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 09/18/2023] [Indexed: 10/06/2023]
Abstract
Thiol-reactive Michael acceptors are commonly used for the formation of chemically cross-linked hydrogels. In this paper, we address the drawbacks of many Michael acceptors by introducing pyridazinediones as new cross-linking agents. Through the use of pyridazinediones and their mono- or dibrominated analogues, we show that the mechanical strength, swelling ratio, and rate of gelation can all be controlled in a pH-sensitive manner. Moreover, we demonstrate that the degradation of pyridazinedione-gels can be induced by the addition of thiols, thus providing a route to responsive or dynamic gels, and that monobromo-pyridazinedione gels are able to support the proliferation of human cells. We anticipate that our results will provide a valuable and complementary addition to the existing toolkit of cross-linking agents, allowing researchers to tune and rationally design the properties of biomedical hydrogels.
Collapse
Affiliation(s)
- Calise Bahou
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Richard J. Spears
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Angela M. Ramírez Rosales
- Department
of Chemistry, University of York, Heslington YO10 5DD, U.K.
- York
Biomedical Research Institute, University
of York, Heslington YO10 5DD, U.K.
| | - Léa N. C. Rochet
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Lydia J. Barber
- Department
of Chemistry, University of York, Heslington YO10 5DD, U.K.
- York
Biomedical Research Institute, University
of York, Heslington YO10 5DD, U.K.
| | - Ksenia S. Stankevich
- Department
of Chemistry, University of York, Heslington YO10 5DD, U.K.
- York
Biomedical Research Institute, University
of York, Heslington YO10 5DD, U.K.
| | - Juliana F. Miranda
- York
Biomedical Research Institute, University
of York, Heslington YO10 5DD, U.K.
| | - Tobias C. Butcher
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Adam M. Kerrigan
- The
York JEOL Nanocentre, University of York, Heslington YO10 5BR, U.K.
| | - Vlado K. Lazarov
- School
of Physics, Engineering, and Technology, University of York, Heslington YO10 5DD, U.K.
| | - William Grey
- York
Biomedical Research Institute, University
of York, Heslington YO10 5DD, U.K.
| | - Vijay Chudasama
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Christopher D. Spicer
- Department
of Chemistry, University of York, Heslington YO10 5DD, U.K.
- York
Biomedical Research Institute, University
of York, Heslington YO10 5DD, U.K.
| |
Collapse
|
6
|
Szijj PA, Gray MA, Ribi MK, Bahou C, Nogueira JCF, Bertozzi CR, Chudasama V. Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer. Nat Chem 2023; 15:1636-1647. [PMID: 37488375 PMCID: PMC10624612 DOI: 10.1038/s41557-023-01280-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 06/21/2023] [Indexed: 07/26/2023]
Abstract
Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a targeted cancer cell's death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T cell engagers (CiTEs) comprise a BiTE core with an added immunomodulatory protein, which serves to reverse cancer-cell immune-dampening strategies, improving efficacy. So far, protein engineering has been the main approach to generate bsAbs and CiTEs, but improved chemical methods for their generation have recently been developed. Homogeneous fragment-based bsAbs constructed from fragment antigen-binding regions (Fabs) can be generated using click chemistry. Here we describe a chemical method to generate biotin-functionalized three-protein conjugates, which include two CiTE molecules, one containing an anti-PD-1 Fab and the other containing an immunomodulatory enzyme, Salmonella typhimurium sialidase. The CiTEs' efficacy was shown to be superior to that of the simpler BiTE scaffold, with the sialidase-containing CiTE inducing substantially enhanced T cell-mediated cytotoxicity in vitro. The chemical method described here, more generally, enables the generation of multi-protein constructs with further biological applications.
Collapse
Affiliation(s)
- Peter A Szijj
- Department of Chemistry, University College London, London, UK
| | - Melissa A Gray
- Department of Chemistry, Sarafan ChEM-H, and Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA
| | - Mikaela K Ribi
- Department of Chemistry, Sarafan ChEM-H, and Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA
| | - Calise Bahou
- Department of Chemistry, University College London, London, UK
| | | | - Carolyn R Bertozzi
- Department of Chemistry, Sarafan ChEM-H, and Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.
| | - Vijay Chudasama
- Department of Chemistry, University College London, London, UK.
| |
Collapse
|
7
|
Zhao Y, Chudasama V, Baker JR. Trifunctional Dibromomaleimide Reagents Built Around A Lysine Scaffold Deliver Site-selective Dual-modality Antibody Conjugation. Chembiochem 2023; 24:e202300356. [PMID: 37548625 DOI: 10.1002/cbic.202300356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 07/11/2023] [Indexed: 08/08/2023]
Abstract
We describe the synthesis and application of a selection of trifunctional reagents for the dual-modality modification of native, solvent accessible disulfide bonds in trastuzumab. The reagents were developed from the dibromomaleimide (DBM) platform with two orthogonal clickable functional groups built around a lysine core. We also describe the development of an aryl diselenide additive which enables antibody disulfide reduction in 4 minutes and a rapid overall reduction-bridging-double click sequence.
Collapse
Affiliation(s)
- Yanbo Zhao
- Department of Chemistry, University College London, 20 Gordon St, London, WC1H 0AJ, UK
| | - Vijay Chudasama
- Department of Chemistry, University College London, 20 Gordon St, London, WC1H 0AJ, UK
| | - James R Baker
- Department of Chemistry, University College London, 20 Gordon St, London, WC1H 0AJ, UK
| |
Collapse
|
8
|
Qian L, Lin X, Gao X, Khan RU, Liao JY, Du S, Ge J, Zeng S, Yao SQ. The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics. Chem Rev 2023. [PMID: 37186942 DOI: 10.1021/acs.chemrev.2c00915] [Citation(s) in RCA: 16] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
The high selectivity and affinity of antibodies toward their antigens have made them a highly valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and genetic approaches have been devised to make antibodies accessible to more "undruggable" targets and equipped with new functions of illustrating or regulating biological processes more precisely. In this Review, in addition to introducing how naked antibodies and various antibody conjugates (such as antibody-drug conjugates, antibody-oligonucleotide conjugates, antibody-enzyme conjugates, etc.) work in therapeutic applications, special attention has been paid to how chemistry tools have helped to optimize the therapeutic outcome (i.e., with enhanced efficacy and reduced side effects) or facilitate the multifunctionalization of antibodies, with a focus on emerging fields such as targeted protein degradation, real-time live-cell imaging, catalytic labeling or decaging with spatiotemporal control as well as the engagement of antibodies inside cells. With advances in modern chemistry and biotechnology, well-designed antibodies and their derivatives via size miniaturization or multifunctionalization together with efficient delivery systems have emerged, which have gradually improved our understanding of important biological processes and paved the way to pursue novel targets for potential treatments of various diseases.
Collapse
Affiliation(s)
- Linghui Qian
- Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Cancer Center, & Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, China
| | - Xuefen Lin
- Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Cancer Center, & Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, China
| | - Xue Gao
- Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Cancer Center, & Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, China
| | - Rizwan Ullah Khan
- Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Cancer Center, & Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, China
| | - Jia-Yu Liao
- Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Cancer Center, & Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, China
| | - Shubo Du
- School of Bioengineering, Dalian University of Technology, Dalian 116024, China
| | - Jingyan Ge
- Key Laboratory of Bioorganic Synthesis of Zhejiang Province, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, China
| | - Su Zeng
- Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Cancer Center, & Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, China
| | - Shao Q Yao
- Department of Chemistry, National University of Singapore, 4 Science Drive 2, Singapore, 117544
| |
Collapse
|
9
|
Thoreau F, Szijj PA, Greene MK, Rochet LNC, Thanasi IA, Blayney JK, Maruani A, Baker JR, Scott CJ, Chudasama V. Modular Chemical Construction of IgG-like Mono- and Bispecific Synthetic Antibodies (SynAbs). ACS CENTRAL SCIENCE 2023; 9:476-487. [PMID: 36968530 PMCID: PMC10037451 DOI: 10.1021/acscentsci.2c01437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Indexed: 06/18/2023]
Abstract
In recent years there has been rising interest in the field of protein-protein conjugation, especially related to bispecific antibodies (bsAbs) and their therapeutic applications. These constructs contain two paratopes capable of binding two distinct epitopes on target molecules and are thus able to perform complex biological functions (mechanisms of action) not available to monospecific mAbs. Traditionally these bsAbs have been constructed through protein engineering, but recently chemical methods for their construction have started to (re)emerge. While these have been shown to offer increased modularity, speed, and for some methods even the inherent capacity for further functionalization (e.g., with small molecule cargo), most of these approaches lacked the ability to include a fragment crystallizable (Fc) modality. The Fc component of IgG antibodies offers effector function and increased half-life. Here we report a first-in-class disulfide rebridging and click-chemistry-based method for the generation of Fc-containing, IgG-like mono- and bispecific antibodies. These are in the FcZ-(FabX)-FabY format, i.e., two distinct Fabs and an Fc, potentially all from different antibodies, attached in a homogeneous and covalent manner. We have dubbed these molecules synthetic antibodies (SynAbs). We have constructed a T cell-engager (TCE) SynAb, FcCD20-(FabHER2)-FabCD3, and have confirmed that it exhibits the expected biological functions, including the ability to kill HER2+ target cells in a coculture assay with T cells.
Collapse
Affiliation(s)
- Fabien Thoreau
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Peter A. Szijj
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Michelle K. Greene
- Patrick
G Johnston Centre for Cancer Research, School of Medicine, Dentistry
and Biomedical Sciences, Queen’s
University Belfast, Belfast BT9 7AEU.K.
| | - Léa N. C. Rochet
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Ioanna A. Thanasi
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Jaine K. Blayney
- Patrick
G Johnston Centre for Cancer Research, School of Medicine, Dentistry
and Biomedical Sciences, Queen’s
University Belfast, Belfast BT9 7AEU.K.
| | - Antoine Maruani
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - James R. Baker
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| | - Christopher J. Scott
- Patrick
G Johnston Centre for Cancer Research, School of Medicine, Dentistry
and Biomedical Sciences, Queen’s
University Belfast, Belfast BT9 7AEU.K.
| | - Vijay Chudasama
- Department
of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
| |
Collapse
|
10
|
Cao W, Maza JC, Chernyak N, Flygare JA, Krska SW, Toste FD, Francis MB. Modification of Cysteine-Substituted Antibodies Using Enzymatic Oxidative Coupling Reactions. Bioconjug Chem 2023; 34:510-517. [PMID: 36787347 DOI: 10.1021/acs.bioconjchem.2c00576] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Cysteines are routinely used as site-specific handles to synthesize antibody-drug conjugates for targeted immunotherapy applications. Michael additions between thiols and maleimides are some of the most common methods for modifying cysteines, but these functional groups can be difficult to prepare on scale, and the resulting linkages have been shown to be reversible under some physiological conditions. Here, we show that the enzyme tyrosinase, which oxidizes conveniently accessed phenols to afford reactive ortho-quinone intermediates, can be used to attach phenolic cargo to cysteines engineered on antibody surfaces. The resulting linkages between the thiols and ortho-quinones are shown to be more resistant than maleimides to reversion under physiological conditions. Using this approach, we construct antibody conjugates bearing cytotoxic payloads, which exhibit targeted cell killing, and further demonstrate this method for the attachment of a variety of cargo to antibodies, including fluorophores and oligonucleotides.
Collapse
Affiliation(s)
- Wendy Cao
- Department of Chemistry, University of California, Berkeley, California 94720, United States
| | - Johnathan C Maza
- Department of Chemistry, University of California, Berkeley, California 94720, United States
| | - Natalia Chernyak
- Department of Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States
| | - John A Flygare
- Department of Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States
| | - Shane W Krska
- Department of Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - F Dean Toste
- Department of Chemistry, University of California, Berkeley, California 94720, United States
| | - Matthew B Francis
- Department of Chemistry, University of California, Berkeley, California 94720, United States
| |
Collapse
|
11
|
Fischer NH, Oliveira MT, Diness F. Chemical modification of proteins - challenges and trends at the start of the 2020s. Biomater Sci 2023; 11:719-748. [PMID: 36519403 DOI: 10.1039/d2bm01237e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Ribosomally expressed proteins perform multiple, versatile, and specialized tasks throughout Nature. In modern times, chemically modified proteins, including improved hormones, enzymes, and antibody-drug-conjugates have become available and have found advanced industrial and pharmaceutical applications. Chemical modification of proteins is used to introduce new functionalities, improve stability or drugability. Undertaking chemical reactions with proteins without compromising their native function is still a core challenge as proteins are large conformation dependent multifunctional molecules. Methods for functionalization ideally should be chemo-selective, site-selective, and undertaken under biocompatible conditions in aqueous buffer to prevent denaturation of the protein. Here the present challenges in the field are discussed and methods for modification of the 20 encoded amino acids as well as the N-/C-termini and protein backbone are presented. For each amino acid, common and traditional modification methods are presented first, followed by more recent ones.
Collapse
Affiliation(s)
- Niklas Henrik Fischer
- Department of Science and Environment, Roskilde University, Universitetsvej 1, DK-4000 Roskilde, Denmark. .,Department of Chemistry, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen, Denmark
| | - Maria Teresa Oliveira
- Department of Chemistry, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen, Denmark
| | - Frederik Diness
- Department of Science and Environment, Roskilde University, Universitetsvej 1, DK-4000 Roskilde, Denmark. .,Department of Chemistry, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen, Denmark
| |
Collapse
|
12
|
Grossenbacher P, Essers MC, Moser J, Singer SA, Häusler S, Stieger B, Rougier JS, Lochner M. Bioorthogonal site-selective conjugation of fluorescent dyes to antibodies: method and potential applications. RSC Adv 2022; 12:28306-28317. [PMID: 36320493 PMCID: PMC9533196 DOI: 10.1039/d2ra05580e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 09/27/2022] [Indexed: 11/17/2022] Open
Abstract
Antibodies are immensely useful tools for biochemical research and have found application in numerous protein detection and purification methods. Moreover, monoclonal antibodies are increasingly utilised as therapeutics or, conjugated to active pharmaceutical ingredients, in targeted chemotherapy. Several reagents and protocols are reported to synthesise fluorescent antibodies for protein target detection and immunofluorescence applications. However, most of these protocols lead to non-selective conjugation, over-labelling or in the worst case antigen binding site modification. Here, we have used the antibody disulphide cleavage and re-bridging strategy to introduce bright fluorescent dyes without loss of the antibody function. The resulting fluorescent IgG1 type antibodies were shown to be effective imaging tools in western blot and direct immunofluorescence experiments.
Collapse
Affiliation(s)
- Philipp Grossenbacher
- Institute of Biochemistry and Molecular Medicine, University of BernBühlstrasse 283012 BernSwitzerland
| | - Maria C. Essers
- Institute of Biochemistry and Molecular Medicine, University of BernBühlstrasse 283012 BernSwitzerland
| | - Joël Moser
- Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of BernFreiestrasse 33012 BernSwitzerland
| | - Simon A. Singer
- Institute of Biochemistry and Molecular Medicine, University of BernBühlstrasse 283012 BernSwitzerland
| | - Stephanie Häusler
- Department of Clinical Pharmacology and Toxicology, University Hospital Zürich, University of ZürichRämistrasse 1008091 ZürichSwitzerland
| | - Bruno Stieger
- Department of Clinical Pharmacology and Toxicology, University Hospital Zürich, University of ZürichRämistrasse 1008091 ZürichSwitzerland
| | - Jean-Sébastien Rougier
- Institute of Biochemistry and Molecular Medicine, University of BernBühlstrasse 283012 BernSwitzerland
| | - Martin Lochner
- Institute of Biochemistry and Molecular Medicine, University of BernBühlstrasse 283012 BernSwitzerland
| |
Collapse
|
13
|
Matsushita T, Maruyama N, Koyama T, Hatano K, Matsuoka K. Modification of Fab Fragments by Dibromopyridazinediones Carrying Mono- and Double-Biotin Functionalities. ACS OMEGA 2022; 7:34554-34562. [PMID: 36188280 PMCID: PMC9520716 DOI: 10.1021/acsomega.2c04379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 09/02/2022] [Indexed: 06/16/2023]
Abstract
To verify the potencies of dibromopyridazinediones with mono- and double-biotin groups, the functions as cysteine-selective biotinylation reagents were evaluated through conjugation with a goat anti-mouse IgG Fab fragment as a functional protein model. The starting Fab was reduced with tris(2-carboxyethyl)phosphine to cleave the disulfide bond and then treated with the reagents. These reagents simultaneously introduced biotin groups into the reduced Fab and re-bridged the disulfide moiety. Furthermore, we demonstrated that the biotin-labeled Fabs were reactive to an antigen and streptavidin.
Collapse
Affiliation(s)
- Takahiko Matsushita
- Area
for Molecular Function, Division of Material Science, Graduate School
of Science and Engineering, Saitama University, Sakura, Saitama 338-8570, Japan
- Medical
Innovation Research Unit (MiU), Advanced Institute of Innovative Technology
(AIIT), Saitama University, Sakura, Saitama 338-8570, Japan
- Health
Sciences and Technology Research Area, Strategic Research Center, Saitama University, Sakura, Saitama 338-8570, Japan
| | - Naoto Maruyama
- Area
for Molecular Function, Division of Material Science, Graduate School
of Science and Engineering, Saitama University, Sakura, Saitama 338-8570, Japan
| | - Tetsuo Koyama
- Area
for Molecular Function, Division of Material Science, Graduate School
of Science and Engineering, Saitama University, Sakura, Saitama 338-8570, Japan
| | - Ken Hatano
- Area
for Molecular Function, Division of Material Science, Graduate School
of Science and Engineering, Saitama University, Sakura, Saitama 338-8570, Japan
- Medical
Innovation Research Unit (MiU), Advanced Institute of Innovative Technology
(AIIT), Saitama University, Sakura, Saitama 338-8570, Japan
- Health
Sciences and Technology Research Area, Strategic Research Center, Saitama University, Sakura, Saitama 338-8570, Japan
| | - Koji Matsuoka
- Area
for Molecular Function, Division of Material Science, Graduate School
of Science and Engineering, Saitama University, Sakura, Saitama 338-8570, Japan
- Medical
Innovation Research Unit (MiU), Advanced Institute of Innovative Technology
(AIIT), Saitama University, Sakura, Saitama 338-8570, Japan
- Health
Sciences and Technology Research Area, Strategic Research Center, Saitama University, Sakura, Saitama 338-8570, Japan
| |
Collapse
|
14
|
Bahou C, Chudasama V. The use of bromopyridazinedione derivatives in chemical biology. Org Biomol Chem 2022; 20:5879-5890. [PMID: 35373804 DOI: 10.1039/d2ob00310d] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Tools that facilitate the chemical modification of peptides and proteins are gaining an increasing amount of interest across many avenues of chemical biology as they enable a plethora of therapeutic, imaging and diagnostic applications. Cysteine residues and disulfide bonds have been highlighted as appealing targets for modification due to the highly homogenous nature of the products that can be formed through their site-selective modification. Amongst the reagents available for the site-selective modification of cysteine(s)/disulfide(s), pyridazinediones (PDs) have played a particularly important and enabling role. In this review, we outline the unique chemical features that make PDs especially well-suited to cysteine/disulfide modification on a wide variety of proteins and peptides, as well as provide context as to the problems solved (and applications enabled) by this technology.
Collapse
Affiliation(s)
- Calise Bahou
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| | - Vijay Chudasama
- UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.
| |
Collapse
|
15
|
Sadraeian M, Junior FFP, Miranda M, Galinskas J, Fernandes RS, da Cruz EF, Fu L, Zhang L, Diaz RS, Cabral-Miranda G, Guimarães FEG. Study of Viral Photoinactivation by UV-C Light and Photosensitizer Using a Pseudotyped Model. Pharmaceutics 2022; 14:pharmaceutics14030683. [PMID: 35336059 PMCID: PMC8955308 DOI: 10.3390/pharmaceutics14030683] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Revised: 03/15/2022] [Accepted: 03/15/2022] [Indexed: 01/27/2023] Open
Abstract
Different light-based strategies have been investigated to inactivate viruses. Herein, we developed an HIV-based pseudotyped model of SARS-CoV-2 (SC2) to study the mechanisms of virus inactivation by using two different strategies; photoinactivation (PI) by UV-C light and photodynamic inactivation (PDI) by Photodithazine photosensitizer (PDZ). We used two pseudoviral particles harboring the Luciferase-IRES-ZsGreen reporter gene with either a SC2 spike on the membrane or without a spike as a naked control pseudovirus. The mechanism of viral inactivation by UV-C and PDZ-based PDI were studied via biochemical characterizations and quantitative PCR on four levels; free-cell viral damage; viral cell entry; DNA integration; and expression of reporter genes. Both UV-C and PDZ treatments could destroy single stranded RNA (ssRNA) and the spike protein of the virus, with different ratios. However, the virus was still capable of binding and entering into the HEK 293T cells expressing angiotensin-converting enzyme 2 (ACE-2). A dose-dependent manner of UV-C irradiation mostly damages the ssRNA, while PDZ-based PDI mostly destroys the spike and viral membrane in concentration and dose-dependent manners. We observed that the cells infected by the virus and treated with either UV-C or PDZ-based PDI could not express the luciferase reporter gene, signifying the viral inactivation, despite the presence of RNA and DNA intact genes.
Collapse
Affiliation(s)
- Mohammad Sadraeian
- Instituto de Física de São Carlos, Universidade de São Paulo, Caixa Postal 369, São Carlos 13560-970, SP, Brazil; (F.F.P.J.); (M.M.); (R.S.F.)
- Institute for Biomedical Materials and Devices (IBMD), Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia; (L.F.); (L.Z.)
- Correspondence: (M.S.); (F.E.G.G.); Tel.: +55-(16)-33739792 (F.E.G.G.)
| | - Fabio Francisco Pinto Junior
- Instituto de Física de São Carlos, Universidade de São Paulo, Caixa Postal 369, São Carlos 13560-970, SP, Brazil; (F.F.P.J.); (M.M.); (R.S.F.)
| | - Marcela Miranda
- Instituto de Física de São Carlos, Universidade de São Paulo, Caixa Postal 369, São Carlos 13560-970, SP, Brazil; (F.F.P.J.); (M.M.); (R.S.F.)
| | - Juliana Galinskas
- Laboratório de Retrovirologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04039-032, SP, Brazil; (J.G.); (E.F.d.C.); (R.S.D.)
| | - Rafaela Sachetto Fernandes
- Instituto de Física de São Carlos, Universidade de São Paulo, Caixa Postal 369, São Carlos 13560-970, SP, Brazil; (F.F.P.J.); (M.M.); (R.S.F.)
| | - Edgar Ferreira da Cruz
- Laboratório de Retrovirologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04039-032, SP, Brazil; (J.G.); (E.F.d.C.); (R.S.D.)
| | - Libing Fu
- Institute for Biomedical Materials and Devices (IBMD), Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia; (L.F.); (L.Z.)
| | - Le Zhang
- Institute for Biomedical Materials and Devices (IBMD), Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia; (L.F.); (L.Z.)
| | - Ricardo Sobhie Diaz
- Laboratório de Retrovirologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04039-032, SP, Brazil; (J.G.); (E.F.d.C.); (R.S.D.)
| | - Gustavo Cabral-Miranda
- Department of Immunology, Institute of Biomedical Sciences, University of São Paulo (ICB/USP), São Paulo 05508-000, SP, Brazil;
- Institute of Research and Education in Child Health (PENSI), São Paulo 01228-200, SP, Brazil
| | - Francisco Eduardo Gontijo Guimarães
- Instituto de Física de São Carlos, Universidade de São Paulo, Caixa Postal 369, São Carlos 13560-970, SP, Brazil; (F.F.P.J.); (M.M.); (R.S.F.)
- Correspondence: (M.S.); (F.E.G.G.); Tel.: +55-(16)-33739792 (F.E.G.G.)
| |
Collapse
|
16
|
Thoreau F, Chudasama V. Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chem Biol 2022; 3:140-169. [PMID: 35360884 PMCID: PMC8826860 DOI: 10.1039/d1cb00082a] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 10/22/2021] [Indexed: 12/02/2022] Open
Abstract
In the past two decades, immunotherapy has established itself as one of the leading strategies for cancer treatment, as illustrated by the exponentially growing number of related clinical trials. This trend was, in part, prompted by the clinical success of both immune checkpoint modulation and immune cell engagement, to restore and/or stimulate the patient's immune system's ability to fight the disease. These strategies were sustained by progress in bispecific antibody production. However, despite the decisive progress made in the treatment of cancer, toxicity and resistance are still observed in some cases. In this review, we initially provide an overview of the monoclonal and bispecific antibodies developed with the objective of restoring immune system functions to treat cancer (cancer immunotherapy), through immune checkpoint modulation, immune cell engagement or a combination of both. Their production, design strategy and impact on the clinical trial landscape are also addressed. In the second part, the concept of multispecific antibody formats, notably MuTICEMs (Multispecific Targeted Immune Cell Engagers & Modulators), as a possible answer to current immunotherapy limitations is investigated. We believe it could be the next step to take for cancer immunotherapy research and expose why bioconjugation chemistry might play a key role in these future developments.
Collapse
Affiliation(s)
- Fabien Thoreau
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| | - Vijay Chudasama
- Department of Chemistry, University College London 20 Gordon Street London WC1H 0AJ UK
| |
Collapse
|
17
|
Juen L, Baltus CB, Gély C, Kervarrec T, Feuillâtre O, Desgranges A, Viaud-Massuard MC, Martin C. Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjug Chem 2022; 33:418-426. [PMID: 35104102 DOI: 10.1021/acs.bioconjchem.2c00015] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
With three clinically approved antibody-drug conjugates targeting HER2, this target is clearly identified to be of interest in oncology. Moreover, the advent of new bioconjugation technologies producing site-specific homogenous conjugates led to the opportunity of developing new medicines linking antibodies and payloads. Here, a new relevant HER2-targeting ADC was obtained by the conjugation of monomethyl auristatin E onto trastuzumab using McSAF Inside bioconjugation technology. The antibody-drug conjugate formed presented an average drug-to-antibody ratio of 4 with a high homogeneity and an excellent stability especially when incubated with human serum albumin or in human plasma. Moreover, it demonstrated a strong efficacy in an HER2 xenograft tumor model in mice, superior to the clinically approved antibody-drug conjugate ado-trastuzumab emtansine, with a complete tumor regression observed both macroscopically and microscopically demonstrating its therapeutic potential.
Collapse
Affiliation(s)
| | | | | | - Thibault Kervarrec
- Department of Pathology, University of Tours, BIP INRA UMR1282 ISP, CHU de Tours, avenue de la République, 37170 Chambray-lès-tours, France
| | | | | | - Marie-Claude Viaud-Massuard
- McSAF, 1 rue Claude Thion, 37000 Tours, France.,IMT, GICC EA7501 University of Tours, 31 avenue Monge, 37200 Tours, France
| | | |
Collapse
|
18
|
Sornay C, Vaur V, Wagner A, Chaubet G. An overview of chemo- and site-selectivity aspects in the chemical conjugation of proteins. ROYAL SOCIETY OPEN SCIENCE 2022; 9:211563. [PMID: 35116160 PMCID: PMC8790347 DOI: 10.1098/rsos.211563] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 12/20/2021] [Indexed: 05/03/2023]
Abstract
The bioconjugation of proteins-that is, the creation of a covalent link between a protein and any other molecule-has been studied for decades, partly because of the numerous applications of protein conjugates, but also due to the technical challenge it represents. Indeed, proteins possess inner physico-chemical properties-they are sensitive and polynucleophilic macromolecules-that make them complex substrates in conjugation reactions. This complexity arises from the mild conditions imposed by their sensitivity but also from selectivity issues, viz the precise control of the conjugation site on the protein. After decades of research, strategies and reagents have been developed to address two aspects of this selectivity: chemoselectivity-harnessing the reacting chemical functionality-and site-selectivity-controlling the reacting amino acid residue-most notably thanks to the participation of synthetic chemistry in this effort. This review offers an overview of these chemical bioconjugation strategies, insisting on those employing native proteins as substrates, and shows that the field is active and exciting, especially for synthetic chemists seeking new challenges.
Collapse
Affiliation(s)
- Charlotte Sornay
- Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, Illkirch-Graffenstaden 67400, France
| | - Valentine Vaur
- Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, Illkirch-Graffenstaden 67400, France
| | - Alain Wagner
- Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, Illkirch-Graffenstaden 67400, France
| | - Guilhem Chaubet
- Bio-Functional Chemistry (UMR 7199), LabEx Medalis, University of Strasbourg, 74 Route du Rhin, Illkirch-Graffenstaden 67400, France
| |
Collapse
|
19
|
Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, Pandiella A. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers (Basel) 2021; 14:154. [PMID: 35008318 PMCID: PMC8750930 DOI: 10.3390/cancers14010154] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Revised: 12/27/2021] [Accepted: 12/27/2021] [Indexed: 12/23/2022] Open
Abstract
During recent years, a number of new compounds against HER2 have reached clinics, improving the prognosis and quality of life of HER2-positive breast cancer patients. Nonetheless, resistance to standard-of-care drugs has motivated the development of novel agents, such as new antibody-drug conjugates (ADCs). The latter are a group of drugs that benefit from the potency of cytotoxic agents whose action is specifically guided to the tumor by the target-specific antibody. Two anti-HER2 ADCs have reached the clinic: trastuzumab-emtansine and, more recently, trastuzumab-deruxtecan. In addition, several other HER2-targeted ADCs are in preclinical or clinical development, some of them with promising signs of activity. In the present review, the structure, mechanism of action, and potential resistance to all these ADCs will be described. Specific attention will be given to discussing novel strategies to circumvent resistance to ADCs.
Collapse
Affiliation(s)
- Elena Díaz-Rodríguez
- Instituto de Biología Molecular y Celular del Cáncer, CSIC-IBSAL and CIBERONC, 37007 Salamanca, Spain; (E.D.-R.); (L.G.-S.)
- Departamento de Bioquímica y Biología Molecular, University of Salamanca, 37007 Salamanca, Spain
| | - Lucía Gandullo-Sánchez
- Instituto de Biología Molecular y Celular del Cáncer, CSIC-IBSAL and CIBERONC, 37007 Salamanca, Spain; (E.D.-R.); (L.G.-S.)
| | - Alberto Ocaña
- Hospital Clínico San Carlos, Centro de Investigación Biomédica en Red de Oncología (CIBERONC), 28040 Madrid, Spain;
| | - Atanasio Pandiella
- Instituto de Biología Molecular y Celular del Cáncer, CSIC-IBSAL and CIBERONC, 37007 Salamanca, Spain; (E.D.-R.); (L.G.-S.)
| |
Collapse
|
20
|
Javaid F, Pilotti C, Camilli C, Kallenberg D, Bahou C, Blackburn J, R Baker J, Greenwood J, Moss SE, Chudasama V. Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chem Biol 2021; 2:1206-1220. [PMID: 34458833 PMCID: PMC8341842 DOI: 10.1039/d1cb00104c] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 05/27/2021] [Indexed: 12/20/2022] Open
Abstract
Leucine-rich alpha-2-glycoprotein 1 (LRG1) is present abundantly in the microenvironment of many tumours where it contributes to vascular dysfunction, which impedes the delivery of therapeutics. In this work we demonstrate that LRG1 is predominantly a non-internalising protein. We report the development of a novel antibody-drug conjugate (ADC) comprising the anti-LRG1 hinge-stabilised IgG4 monoclonal antibody Magacizumab coupled to the anti-mitotic payload monomethyl auristatin E (MMAE) via a cleavable dipeptide linker using the site-selective disulfide rebridging dibromopyridazinedione (diBrPD) scaffold. It is demonstrated that this ADC retains binding post-modification, is stable in serum and effective in in vitro cell studies. We show that the extracellular LRG1-targeting ADC provides an increase in survival in vivo when compared against antibody alone and similar anti-tumour activity when compared against standard chemotherapy, but without undesired side-effects. LRG1 targeting through this ADC presents a novel and effective proof-of-concept en route to improving the efficacy of cancer therapeutics.
Collapse
Affiliation(s)
- Faiza Javaid
- UCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK
- UCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK
| | - Camilla Pilotti
- UCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK
| | - Carlotta Camilli
- UCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK
| | - David Kallenberg
- UCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK
| | - Calise Bahou
- UCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK
| | - Jack Blackburn
- UCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK
| | - James R Baker
- UCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK
| | - John Greenwood
- UCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK
| | - Stephen E Moss
- UCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK
| | - Vijay Chudasama
- UCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK
| |
Collapse
|
21
|
Richards DA, Thomas MR, Szijj PA, Foote J, Chen Y, Nogueira JCF, Chudasama V, Stevens MM. Employing defined bioconjugates to generate chemically functionalised gold nanoparticles for in vitro diagnostic applications. NANOSCALE 2021; 13:11921-11931. [PMID: 34190286 PMCID: PMC8280965 DOI: 10.1039/d1nr02584h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Accepted: 06/22/2021] [Indexed: 06/13/2023]
Abstract
Novel methods for introducing chemical and biological functionality to the surface of gold nanoparticles serve to increase the utility of this class of nanomaterials across a range of applications. To date, methods for functionalising gold surfaces have relied upon uncontrollable non-specific adsorption, bespoke chemical linkers, or non-generalisable protein-protein interactions. Herein we report a versatile method for introducing functionality to gold nanoparticles by exploiting the strong interaction between chemically functionalised bovine serum albumin (f-BSA) and citrate-capped gold nanoparticles (AuNPs). We establish the generalisability of the method by introducing a variety of functionalities to gold nanoparticles using cheap, commercially available chemical linkers. The utility of this approach is further demonstrated through the conjugation of the monoclonal antibody Ontruzant to f-BSA-AuNPs using inverse electron-demand Diels-Alder (iEDDA) click chemistry, a hitherto unexplored chemistry for AuNP-IgG conjugation. Finally, we show that the AuNP-Ontruzant particles generated via f-BSA-AuNPs have a greater affinity for their target in a lateral flow format when compared to conventional physisorption, highlighting the potential of this technology for producing sensitive diagnostic tests.
Collapse
Affiliation(s)
- Daniel A. Richards
- Department of Materials, Imperial College LondonLondonUK
- Department of Bioengineering, Imperial College LondonUK
- Institute of Biomedical Engineering, Imperial College LondonLondonUK
| | - Michael R. Thomas
- Department of Materials, Imperial College LondonLondonUK
- Department of Bioengineering, Imperial College LondonUK
- Institute of Biomedical Engineering, Imperial College LondonLondonUK
- London Centre for Nanotechnology, University College LondonLondonUK
- Department of Biochemical Engineering, University College LondonWC1E 6BT LondonUK
| | - Peter A. Szijj
- Department of Chemistry, University College LondonLondonUK
| | - James Foote
- Department of Materials, Imperial College LondonLondonUK
- Department of Bioengineering, Imperial College LondonUK
- Institute of Biomedical Engineering, Imperial College LondonLondonUK
| | - Yiyun Chen
- Department of Materials, Imperial College LondonLondonUK
- Department of Bioengineering, Imperial College LondonUK
- Institute of Biomedical Engineering, Imperial College LondonLondonUK
| | | | | | - Molly M. Stevens
- Department of Materials, Imperial College LondonLondonUK
- Department of Bioengineering, Imperial College LondonUK
- Institute of Biomedical Engineering, Imperial College LondonLondonUK
- Department of Medical Biochemistry and BiophysicsStockholmSweden
| |
Collapse
|
22
|
Sadraeian M, da Cruz EF, Boyle RW, Bahou C, Chudasama V, Janini LM, Diaz RS, Guimarães FEG. Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV. ACS OMEGA 2021; 6:16524-16534. [PMID: 34235324 PMCID: PMC8246456 DOI: 10.1021/acsomega.1c01721] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 05/27/2021] [Indexed: 06/01/2023]
Abstract
HIV-infected cells persist for decades in patients administered with antiretroviral therapy (ART). Meanwhile, an alarming surge in drug-resistant HIV viruses has been occurring. Addressing these issues, we propose the application of photoimmunotherapy (PIT) against not only HIV Env-expressing cells but also HIV. Previously, we showed that a human anti-gp41 antibody (7B2) conjugated to cationic or anionic photosensitizers (PSs) could specifically target and kill the HIV Env-expressing cells. Here, our photolysis studies revealed that the binding of photoimmunoconjugates (PICs) on the membrane of HIV Env-expressing cells is sufficient to induce necrotic cell death due to physical damage to the membrane by singlet oxygen, which is independent of the type of PSs. This finding persuaded us to study the virus photoinactivation of PICs using two HIV-1 strains, X4 HIV-1 NL4-3 and JR-CSF virus. We observed that the PICs could destroy the viral strains, probably via physical damage on the HIV envelope. In conclusion, we report the application of PIT as a possible dual-tool for HIV immunotherapy and ART by killing HIV-expressing cells and cell-free HIV, respectively.
Collapse
Affiliation(s)
- Mohammad Sadraeian
- São Carlos Institute of
Physics, University of São Paulo, Caixa Postal 369, São Carlos, SP CEP 13560-970, Brazil
| | | | - Ross W. Boyle
- Department
of Chemistry, University of Hull, Cottingham Road, Hull HU6 7RX, U.K.
| | - Calise Bahou
- Department
of Chemistry, University College London, London WC1H 0AJ, U.K.
| | - Vijay Chudasama
- Department
of Chemistry, University College London, London WC1H 0AJ, U.K.
| | | | - Ricardo Sobhie Diaz
- Laboratório
de Retrovirologia, Universidade Federal
de São Paulo, São
Paulo, Brazil
| | - Francisco E. G. Guimarães
- São Carlos Institute of
Physics, University of São Paulo, Caixa Postal 369, São Carlos, SP CEP 13560-970, Brazil
| |
Collapse
|
23
|
Bahou C, Szijj PA, Spears RJ, Wall A, Javaid F, Sattikar A, Love EA, Baker JR, Chudasama V. A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability. Bioconjug Chem 2021; 32:672-679. [PMID: 33710874 PMCID: PMC8154211 DOI: 10.1021/acs.bioconjchem.1c00057] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 03/04/2021] [Indexed: 02/08/2023]
Abstract
Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology. Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo. Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents. However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood. Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension. Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue. Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation. Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione. The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide. This platform provides a rare opportunity to combine up to three functionalities on a protein in a site-selective fashion. Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
Collapse
Affiliation(s)
- Calise Bahou
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Peter A. Szijj
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Richard J. Spears
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Archie Wall
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Faiza Javaid
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Afrah Sattikar
- LifeArc,
Accelerator Building, SBC Open Innovation Campus, SG1 2FX, Stevenage, United Kingdom
| | - Elizabeth A. Love
- LifeArc,
Accelerator Building, SBC Open Innovation Campus, SG1 2FX, Stevenage, United Kingdom
| | - James R. Baker
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
| | - Vijay Chudasama
- Department
of Chemistry, University College London, 20 Gordon Street, WC1H OAJ, London, United Kingdom
- Research
Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-004 Lisbon, Portugal
| |
Collapse
|
24
|
Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, Ou X, Fowler E, Ashman N, Takada Y, Isidro-Llobet A, Parker JS, Carroll JS, Spring DR. Site-selective modification strategies in antibody-drug conjugates. Chem Soc Rev 2021; 50:1305-1353. [PMID: 33290462 DOI: 10.1039/d0cs00310g] [Citation(s) in RCA: 199] [Impact Index Per Article: 66.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Antibody-drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. They have garnered widespread interest in drug discovery, particularly in oncology, as discrimination between healthy and malignant tissues or cells can be achieved. Nine ADCs have received approval from the US Food and Drug Administration and more than 80 others are currently undergoing clinical investigations for a range of solid tumours and haematological malignancies. Extensive research over the past decade has highlighted the critical nature of the linkage strategy adopted to attach the payload to the antibody. Whilst early generation ADCs were primarily synthesised as heterogeneous mixtures, these were found to have sub-optimal pharmacokinetics, stability, tolerability and/or efficacy. Efforts have now shifted towards generating homogeneous constructs with precise drug loading and predetermined, controlled sites of attachment. Homogeneous ADCs have repeatedly demonstrated superior overall pharmacological profiles compared to their heterogeneous counterparts. A wide range of methods have been developed in the pursuit of homogeneity, comprising chemical or enzymatic methods or a combination thereof to afford precise modification of specific amino acid or sugar residues. In this review, we discuss advances in chemical and enzymatic methods for site-specific antibody modification that result in the generation of homogeneous ADCs.
Collapse
Affiliation(s)
- Stephen J Walsh
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
Bispecific antibodies (bsAbs) target two different epitopes. These are an up-and-coming class of biologics, with two such therapeutics (emicizumab and blinatumomab) FDA approved and on the market, and many more in clinical trials. While the first reported bsAbs were constructed by chemical methods, this approach has fallen out of favour with the advent of modern genetic engineering techniques and, nowadays, the vast majority of bsAbs are produced by protein engineering. However, in recent years, relying on innovations in the fields of bioconjugation and bioorthogonal click chemistry, new chemical methods have appeared that have the potential to be competitive with protein engineering techniques and, indeed, hold some advantages. These approaches offer modularity, reproducibility and batch-to-batch consistency, as well as the integration of handles, whereby additional cargo molecules can be attached easily, e.g. to generate bispecific antibody-drug conjugates. The linker between the antibodies/antibody fragments can also be easily varied, and new formats (types, defined by structural properties or by construction methodology) can be generated rapidly. These attributes offer the potential to revolutionize the field. Here, we review chemical methods for the generation of bsAbs, showing that the newest examples of these techniques are worthy competitors to the industry-standard expression-based strategies.
Collapse
|
26
|
Abstract
Preparation of antibody-drug conjugates (ADCs) with a highly homogeneous drug loading in general requires site-selective conjugation of a cytotoxic payload. Typically, functionality utilized for attachment of the payload is achieved through engineering of suitable chemical handles or by enzymatic modification of the antibody. Relatively few methods to produce ADCs with homogeneous drug loading via endogenous amino acid conjugation have been developed. Herein we describe a robust method for the conjugation of antibodies using a cysteine rebridging approach to produce ADCs with highly homogeneous drug-to-antibody ratios (DAR) at the native interchain disulfides, called ThioBridge®. The process described relies upon an elegant cascade of addition-elimination reactions carried out under mild aqueous conditions that can be readily applied to wild-type antibodies without the need for prior modification via recombinant or enzymatic means. Using this method, conversions to a conserved DAR ADC are typically in the range of 70-95% and overall process yields of >70% are readily achieved.
Collapse
|
27
|
Yin Z, Du M, Chen D, Zhang W, Huang W, Wu X, Yan S. Rapid structural discrimination of IgG antibodies by multicharge-state collision-induced unfolding. RSC Adv 2021; 11:36502-36510. [PMID: 35494361 PMCID: PMC9043582 DOI: 10.1039/d1ra06486j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2021] [Accepted: 11/06/2021] [Indexed: 11/29/2022] Open
Abstract
Immunoglobulin G (IgG) antibodies are an important class of biotherapeutics that target various diseases, such as cancers, neurodegenerative disorders, and autoimmune diseases, yet rapid discrimination of IgG antibodies remains a great challenge due to heterogeneity, flexibility, and large size. Herein, we demonstrate a simplified multicharge-state collision-induced unfolding (CIU) method for rapid differentiation of four IgG isotypes that differ in terms of the numbers and patterns of disulfide bonds, bypassing tedious single charge-state selection in advance. The results presented herein reveal that gas-phase unfolding behaviors have a strong dependence on charge states outside IgG surfaces; therefore, multicharge-state CIU analysis of IgG subtypes could offer a great opportunity to gain deeper insights into their gas-phase structural differentiation. The full discrimination of IgG antibody isoforms that possess different disulfide bond numbers and even subtle disulfide bonding patterns can be achieved based on their charge-dependent gas-phase unfolding behaviors and root-mean square deviation in CIU difference spectra. Taken together, the incorporation of all charge states observed in a native ion mobility-mass spectrometry (IM-MS) experiment to CIU analysis could make this strategy sensitive to more subtle structural discrepancies, facilitating the rapid discrimination and evaluation of innovative structurally similar biotherapeutic candidates with unexplored functions. A simplified multicharge-state collision-induced unfolding (CIU) method was proposed for rapid differentiation of IgG isotypes that differ in terms of the numbers and patterns of disulfide bonds.![]()
Collapse
Affiliation(s)
- Zhibin Yin
- Guangdong Key Laboratory for Crop Germplasm Resources Preservation and Utilization, Agro-biological Gene Research Center, Guangdong Academy of Agricultural Sciences, Guangzhou, 510640, China
| | - Mingyi Du
- Guangdong Key Laboratory for Crop Germplasm Resources Preservation and Utilization, Agro-biological Gene Research Center, Guangdong Academy of Agricultural Sciences, Guangzhou, 510640, China
- State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Key Laboratory of Natural Pesticide and Chemical Biology of the Ministry of Education, South China Agricultural University, Guangzhou, 510642, China
| | - Dong Chen
- Guangdong Key Laboratory for Crop Germplasm Resources Preservation and Utilization, Agro-biological Gene Research Center, Guangdong Academy of Agricultural Sciences, Guangzhou, 510640, China
- State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Key Laboratory of Natural Pesticide and Chemical Biology of the Ministry of Education, South China Agricultural University, Guangzhou, 510642, China
| | - Wenyang Zhang
- Guangdong Key Laboratory for Crop Germplasm Resources Preservation and Utilization, Agro-biological Gene Research Center, Guangdong Academy of Agricultural Sciences, Guangzhou, 510640, China
| | - Wenjie Huang
- Guangdong Key Laboratory for Crop Germplasm Resources Preservation and Utilization, Agro-biological Gene Research Center, Guangdong Academy of Agricultural Sciences, Guangzhou, 510640, China
| | - Xinzhou Wu
- State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Key Laboratory of Natural Pesticide and Chemical Biology of the Ministry of Education, South China Agricultural University, Guangzhou, 510642, China
| | - Shijuan Yan
- Guangdong Key Laboratory for Crop Germplasm Resources Preservation and Utilization, Agro-biological Gene Research Center, Guangdong Academy of Agricultural Sciences, Guangzhou, 510640, China
| |
Collapse
|
28
|
Sadraeian M, Bahou C, da Cruz EF, Janini LMR, Sobhie Diaz R, Boyle RW, Chudasama V, Eduardo Gontijo Guimarães F. Photoimmunotherapy Using Cationic and Anionic Photosensitizer-Antibody Conjugates against HIV Env-Expressing Cells. Int J Mol Sci 2020; 21:E9151. [PMID: 33271741 PMCID: PMC7730620 DOI: 10.3390/ijms21239151] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 11/20/2020] [Accepted: 11/21/2020] [Indexed: 12/11/2022] Open
Abstract
Different therapeutic strategies have been investigated to target and eliminate HIV-1-infected cells by using armed antibodies specific to viral proteins, with varying degrees of success. Herein, we propose a new strategy by combining photodynamic therapy (PDT) with HIV Env-targeted immunotherapy, and refer to it as HIV photoimmunotherapy (PIT). A human anti-gp41 antibody (7B2) was conjugated to two photosensitizers (PSs) with different charges through different linking strategies; "Click" conjugation by using an azide-bearing porphyrin attached via a disulfide bridge linker with a drug-to-antibody ratio (DAR) of exactly 4, and "Lysine" conjugation by using phthalocyanine IRDye 700DX dye with average DARs of 2.1, 3.0 and 4.4. These photo-immunoconjugates (PICs) were compared via biochemical and immunological characterizations regarding the dosimetry, solubility, and cell targeting. Photo-induced cytotoxicity of the PICs were compared using assays for apoptosis, reactive oxygen species (ROS), photo-cytotoxicity, and confocal microscopy. Targeted phototoxicity seems to be primarily dependent on the binding of PS-antibody to the HIV antigen on the cell membrane, whilst being independent of the PS type. This is the first report of the application of PIT for HIV immunotherapy by killing HIV Env-expressing cells.
Collapse
Affiliation(s)
- Mohammad Sadraeian
- São Carlos Institute of Physics, University of São Paulo, São Carlos, SP 13566-590, Brazil;
| | - Calise Bahou
- Department of Chemistry, University College London, London WC1H 0AJ, UK;
| | - Edgar Ferreira da Cruz
- Laboratório de Retrovirologia, Disciplina de Microbiologia, Departamento de Microbiologia Imunologia Parasitologia, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil; (E.F.d.C.); (L.M.R.J.); (R.S.D.)
| | - Luíz Mário Ramos Janini
- Laboratório de Retrovirologia, Disciplina de Microbiologia, Departamento de Microbiologia Imunologia Parasitologia, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil; (E.F.d.C.); (L.M.R.J.); (R.S.D.)
| | - Ricardo Sobhie Diaz
- Laboratório de Retrovirologia, Disciplina de Microbiologia, Departamento de Microbiologia Imunologia Parasitologia, Universidade Federal de São Paulo, São Paulo, SP 04039-032, Brazil; (E.F.d.C.); (L.M.R.J.); (R.S.D.)
| | - Ross W. Boyle
- Department of Chemistry, University of Hull, Cottingham Road, Hull HU6 7RX, UK;
| | - Vijay Chudasama
- Department of Chemistry, University College London, London WC1H 0AJ, UK;
| | | |
Collapse
|
29
|
Greene MK, Chen T, Robinson E, Straubinger NL, Minx C, Chan DKW, Wang J, Burrows JF, Van Schaeybroeck S, Baker JR, Caddick S, Longley DB, Mager DE, Straubinger RM, Chudasama V, Scott CJ. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. Br J Cancer 2020; 123:1502-1512. [PMID: 32913288 PMCID: PMC7653048 DOI: 10.1038/s41416-020-01046-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Revised: 07/27/2020] [Accepted: 08/13/2020] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Antibody-drug conjugate (ADC) construction poses numerous challenges that limit clinical progress. In particular, common bioconjugation methods afford minimal control over the site of drug coupling to antibodies. Here, such difficulties are overcome through re-bridging of the inter-chain disulfides of cetuximab (CTX) with auristatin-bearing pyridazinediones, to yield a highly refined anti-epidermal growth factor receptor (EGFR) ADC. METHODS In vitro and in vivo assessment of ADC activity was performed in KRAS mutant pancreatic cancer (PaCa) models with known resistance to CTX therapy. Computational modelling was employed for quantitative prediction of tumour response to various ADC dosing regimens. RESULTS Site-selective coupling of an auristatin to CTX yielded an ADC with an average drug:antibody ratio (DAR) of 3.9, which elicited concentration- and EGFR-dependent cytotoxicity at sub-nanomolar potency in vitro. In human xenografts, the ADC inhibited tumour growth and prolonged survival, with no overt signs of toxicity. Key insights into factors governing ADC efficacy were obtained through a robust mathematical framework, including target-mediated dispositional effects relating to antigen density on tumour cells. CONCLUSIONS Together, our findings offer renewed hope for CTX in PaCa therapy, demonstrating that it may be reformatted as a next-generation ADC and combined with a predictive modelling tool to guide successful translation.
Collapse
Affiliation(s)
- Michelle K Greene
- The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | - Ting Chen
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
| | - Eifion Robinson
- Department of Chemistry, University College London, London, UK
| | - Ninfa L Straubinger
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
| | - Charlene Minx
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
| | - Darren K W Chan
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
| | - Jun Wang
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
| | | | - Sandra Van Schaeybroeck
- The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | - James R Baker
- Department of Chemistry, University College London, London, UK
| | - Stephen Caddick
- Department of Chemistry, University College London, London, UK
| | - Daniel B Longley
- The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | - Donald E Mager
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
| | - Robert M Straubinger
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
- Department of Pharmacology & Cancer Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA.
| | - Vijay Chudasama
- Department of Chemistry, University College London, London, UK.
| | - Christopher J Scott
- The Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
| |
Collapse
|
30
|
Nieto C, Vega MA, Martín del Valle EM. Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine. NANOMATERIALS (BASEL, SWITZERLAND) 2020; 10:E1674. [PMID: 32859026 PMCID: PMC7557948 DOI: 10.3390/nano10091674] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Revised: 08/24/2020] [Accepted: 08/24/2020] [Indexed: 02/07/2023]
Abstract
HER2 overexpression, which occurs in a fifth of diagnosed breast cancers as well as in other types of solid tumors, has been traditionally linked to greater aggressiveness. Nevertheless, the clinical introduction of trastuzumab has helped to improve HER2-positive patients' outcomes. As a consequence, nanotechnology has taken advantage of the beneficial effects of the administration of this antibody and has employed it to develop HER2-targeting nanomedicines with promising therapeutic activity and limited toxicity. In this review, the molecular pathways that could be responsible for trastuzumab antitumor activity will be briefly summarized. In addition, since the conjugation strategies that are followed to develop targeting nanomedicines are essential to maintaining their efficacy and tolerability, the ones most employed to decorate drug-loaded nanoparticles and liposomes with trastuzumab will be discussed here. Thus, the advantages and disadvantages of performing this trastuzumab conjugation through adsorption or covalent bindings (through carbodiimide, maleimide, and click-chemistry) will be described, and several examples of targeting nanovehicles developed following these strategies will be commented on. Moreover, conjugation methods employed to synthesized trastuzumab-based antibody drug conjugates (ADCs), among which T-DM1 is well known, will be also examined. Finally, although trastuzumab-decorated nanoparticles and liposomes and trastuzumab-based ADCs have proven to have better selectivity and efficacy than loaded drugs, trastuzumab administration is sometimes related to side toxicities and the apparition of resistances. For this reason also, this review focuses at last on the important role that newer antibodies and peptides are acquiring these days in the development of HER2-targeting nanomedicines.
Collapse
Affiliation(s)
- Celia Nieto
- Departamento de Ingeniería Química, Facultad de Ciencias Químicas, Universidad de Salamanca, 37008 Salamanca, Spain;
| | | | - Eva M. Martín del Valle
- Departamento de Ingeniería Química, Facultad de Ciencias Químicas, Universidad de Salamanca, 37008 Salamanca, Spain;
| |
Collapse
|
31
|
Maneiro M, Forte N, Shchepinova MM, Kounde CS, Chudasama V, Baker JR, Tate EW. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chem Biol 2020; 15:1306-1312. [PMID: 32338867 PMCID: PMC7309268 DOI: 10.1021/acschembio.0c00285] [Citation(s) in RCA: 159] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 04/27/2020] [Indexed: 01/01/2023]
Abstract
Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery. Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity and do not discriminate between cells of different types. Here, we describe a strategy for selective protein degradation in a specific cell type. We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab-PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody-PROTAC internalization, releasing the active PROTAC and inducing catalytic protein degradation. We show that 3 selectively targets bromodomain-containing protein 4 (BRD4) for degradation only in HER2 positive breast cancer cell lines, while sparing HER2 negative cells. Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 positive cells, leading to the release of active PROTAC in quantities sufficient to induce potent BRD4 degradation. These studies demonstrate proof-of-concept for tissue-specific BRD4 degradation, overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.
Collapse
Affiliation(s)
- María Maneiro
- Department
of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London, W12 0BZ, United Kingdom
| | - Nafsika Forte
- Department
of Chemistry, University College London, 20 Gordon St, London, WC1H 0AJ, United
Kingdom
| | - Maria M. Shchepinova
- Department
of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London, W12 0BZ, United Kingdom
| | - Cyrille S. Kounde
- Department
of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London, W12 0BZ, United Kingdom
| | - Vijay Chudasama
- Department
of Chemistry, University College London, 20 Gordon St, London, WC1H 0AJ, United
Kingdom
| | - James Richard Baker
- Department
of Chemistry, University College London, 20 Gordon St, London, WC1H 0AJ, United
Kingdom
| | - Edward W. Tate
- Department
of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London, W12 0BZ, United Kingdom
| |
Collapse
|
32
|
Marquard AN, Carlson JCT, Weissleder R. Expanding the Scope of Antibody Rebridging with New Pyridazinedione-TCO Constructs. Bioconjug Chem 2020; 31:1616-1623. [PMID: 32286045 PMCID: PMC7788567 DOI: 10.1021/acs.bioconjchem.0c00155] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Disulfide rebridging methods have recently emerged as a route to hinge region-specific antibody modification, and there exist numerous examples of successful rebridging chemistry applied to clinically relevant human IgG1 antibodies. Here, dibromopyridazinedione disulfide rebridging is adapted to fast trans-cyclooctene/tetrazine (TCO/Tz) bioorthogonal ligations and extended beyond therapeutic human IgG1 antibodies for the first time to include mouse and rat monoclonal antibodies integral to multiplexed analytical diagnostics. In spite of a common architecture, only a subset of antibody host species and IgG isotype subclasses can be rebridged, highlighting the intricate relationship between hinge region sequence, structure, biological activity, and the conjugation chemistry of IgG antibodies.
Collapse
Affiliation(s)
- Angela N. Marquard
- Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA
| | - Jonathan C. T. Carlson
- Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA
- Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, MA
- Department of Systems Biology, Harvard Medical School, Boston, MA
| |
Collapse
|
33
|
Maruani A, Szijj PA, Bahou C, Nogueira JCF, Caddick S, Baker JR, Chudasama V. A Plug-and-Play Approach for the De Novo Generation of Dually Functionalized Bispecifics. Bioconjug Chem 2020; 31:520-529. [DOI: 10.1021/acs.bioconjchem.0c00002] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Antoine Maruani
- Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom
| | - Peter A. Szijj
- Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom
| | - Calise Bahou
- Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom
| | - João C. F. Nogueira
- Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom
| | - Stephen Caddick
- Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom
| | - James R. Baker
- Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom
| | - Vijay Chudasama
- Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal
| |
Collapse
|
34
|
Fernández M, Shamsabadi A, Chudasama V. Fine-tuning thio-pyridazinediones as SMDC scaffolds (with intracellular thiol release via a novel self-immolative linker). Chem Commun (Camb) 2020; 56:1125-1128. [PMID: 31894778 DOI: 10.1039/c9cc08744c] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Herein we report the synthesis of a library of thioalkyl- and thioaryl-pyridazinediones for thiol-based self-immolative release of cargo. A bisthioaryl-pyridazinedione is shown to be stable to serum protein albumin but unstable in intracellular conditions. A derivatised analogue underwent self-immolative degradation in cellular thiol conditions as evidenced by LC-MS/release of a turn-on fluorescence fluorophore; versatility of the thiol-pyridazinedione is demonstrated through synthesis of SMDC precursors that contain three different functional groups on the same central molecule.
Collapse
|
35
|
Huang R, Sheng Y, Wei D, Yu J, Chen H, Jiang B. Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates. Eur J Med Chem 2020; 190:112080. [PMID: 32018094 DOI: 10.1016/j.ejmech.2020.112080] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Revised: 01/16/2020] [Accepted: 01/17/2020] [Indexed: 12/18/2022]
Abstract
Disulfide re-bridging strategy has demonstrated significant advantages in the construction of homogeneous antibody drug conjugates (ADCs). However, a major issue that disulfide scrambling at the hinge region of antibody leads to the formation of "half-antibody" has appeared for many re-bridging linkers. We present bis(vinylsulfonyl)piperazines (BVP) as efficient linkers to selectively re-bridge disulfides at the antigen-binding fragment (Fab) regions and produce highly homogeneous conjugates with a loading of two drugs without disulfide scrambling. We also found that optically active (S)-configuration linkers led to more sufficient conjugation compared with (R)-configuration. The BVP-linked ADCs demonstrated superior efficacy and antigen-selectivity in vitro cytotoxicity.
Collapse
Affiliation(s)
- Rong Huang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai, 201210, China; University of Chinese Academy of Sciences, 19A Yuquan Road, Shijingshan District, Beijing, 100049, China
| | - Yao Sheng
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai, 201210, China
| | - Ding Wei
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai, 201210, China; University of Chinese Academy of Sciences, 19A Yuquan Road, Shijingshan District, Beijing, 100049, China
| | - Jianghui Yu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai, 201210, China; University of Chinese Academy of Sciences, 19A Yuquan Road, Shijingshan District, Beijing, 100049, China
| | - Hongli Chen
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai, 201210, China.
| | - Biao Jiang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai, 201210, China.
| |
Collapse
|
36
|
Dabiri M, Lehi NF, Osmani C, Movahed SK. Palladium-Catalyzed Direct ortho
-C-H Bond Sulfonylation and Halogenation of Phthalazine-1,4-diones. European J Org Chem 2019. [DOI: 10.1002/ejoc.201901055] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Minoo Dabiri
- Faculty of Chemistry and Petroleum Sciences; Shahid Beheshti University; District 1, Daneshjou Boulevard 1983969411 Tehran Tehran Province Iran (Islamic Republic of)
| | - Noushin Farajinia Lehi
- Faculty of Chemistry and Petroleum Sciences; Shahid Beheshti University; District 1, Daneshjou Boulevard 1983969411 Tehran Tehran Province Iran (Islamic Republic of)
| | - Chiman Osmani
- Faculty of Chemistry and Petroleum Sciences; Shahid Beheshti University; District 1, Daneshjou Boulevard 1983969411 Tehran Tehran Province Iran (Islamic Republic of)
| | - Siyavash Kazemi Movahed
- Faculty of Chemistry and Petroleum Sciences; Shahid Beheshti University; District 1, Daneshjou Boulevard 1983969411 Tehran Tehran Province Iran (Islamic Republic of)
| |
Collapse
|
37
|
Forte N, Benni I, Karu K, Chudasama V, Baker JR. Cysteine-to-lysine transfer antibody fragment conjugation. Chem Sci 2019; 10:10919-10924. [PMID: 32190247 PMCID: PMC7066670 DOI: 10.1039/c9sc03825f] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Accepted: 10/11/2019] [Indexed: 12/11/2022] Open
Abstract
Site-selective antibody fragment conjugation is achieved by using a disulfide bond to ‘hook’ and deliver thioester acylating agents to specific lysines.
The modification of lysine residues with acylating agents has represented a ubiquitous approach to the construction of antibody conjugates, with the resulting amide bonds being robustly stable and clinically validated. However, the conjugates are highly heterogeneous, due to the presence of numerous lysines on the surface of the protein, and greater control of the sites of conjugation are keenly sought. Here we present a novel approach to achieve the targeted modification of lysines distal to an antibody fragment's binding site, using a disulfide bond as a temporary ‘hook’ to deliver the acylating agent. This cysteine-to-lysine transfer (CLT) methodology offers greatly improved homogeneity of lysine conjugates, whilst retaining the advantages offered by the formation of amide linkages.
Collapse
Affiliation(s)
- Nafsika Forte
- Department of Chemistry , University College London , 20 Gordon Street , London , WC1H 0AJ , UK . ;
| | - Irene Benni
- Department of Chemistry , University College London , 20 Gordon Street , London , WC1H 0AJ , UK . ;
| | - Kersti Karu
- Department of Chemistry , University College London , 20 Gordon Street , London , WC1H 0AJ , UK . ;
| | - Vijay Chudasama
- Department of Chemistry , University College London , 20 Gordon Street , London , WC1H 0AJ , UK . ; .,Research Institute for Medicines (iMed.ULisboa) , Faculty of Pharmacy , Universidade de Lisboa , Lisbon , Portugal
| | - James R Baker
- Department of Chemistry , University College London , 20 Gordon Street , London , WC1H 0AJ , UK . ;
| |
Collapse
|
38
|
Bahou C, Richards DA, Maruani A, Love EA, Javaid F, Caddick S, Baker JR, Chudasama V. Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones. Org Biomol Chem 2019; 16:1359-1366. [PMID: 29405223 PMCID: PMC6058253 DOI: 10.1039/c7ob03138f] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Herein we report novel protocols for the generation and application of dibromopyridazinediones, an exciting class of disulfide bridging reagents.
Due to their exquisite cysteine-selectivity, excellent stability, and ability to functionally rebridge disulfide bonds, dibromopyridazinediones are emerging as an exciting new class of bioconjugation reagents, particularly in the field of antibody conjugation. Despite this, relatively little work has been performed on the optimisation of their synthesis and subsequent reaction with immunoglobulins. Herein we present a novel synthetic route towards functionalised dibromopyridazinediones, proceeding via an isolatable dibromopyridazinedione-NHS ester. Reaction of this activated intermediate with a variety of amines produces functional dibromopyridazinediones in good to excellent yields. The disulfide rebridging capacity of these reagents was optimised on the clinically relevant IgG1 trastuzumab, resulting in a general method which allows for the generation of site-selectively modified native trastuzumab with over 90% homogeneity (no disulfide scrambling) without the need for protein engineering or enzymatic conjugation.
Collapse
Affiliation(s)
- Calise Bahou
- Department of Chemistry, University College London, London, UK.
| | | | - Antoine Maruani
- Department of Chemistry, University College London, London, UK.
| | - Elizabeth A Love
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, UK
| | - Faiza Javaid
- Department of Chemistry, University College London, London, UK.
| | - Stephen Caddick
- Department of Chemistry, University College London, London, UK.
| | - James R Baker
- Department of Chemistry, University College London, London, UK.
| | - Vijay Chudasama
- Department of Chemistry, University College London, London, UK. and Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| |
Collapse
|
39
|
Bahou C, Love EA, Leonard S, Spears RJ, Maruani A, Armour K, Baker JR, Chudasama V. Disulfide Modified IgG1: An Investigation of Biophysical Profile and Clinically Relevant Fc Interactions. Bioconjug Chem 2019; 30:1048-1054. [PMID: 30855134 DOI: 10.1021/acs.bioconjchem.9b00174] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Modification of immunoglobulin G (IgG) 1 proteins in cancer treatment is a rapidly growing field of research. Antibody-drug conjugates (ADCs) exploit the targeted nature of this immunotherapy by conjugating highly potent drugs to antibodies, allowing for effective transport of cargo(s) to cancerous cells. Of the many bioconjugation strategies now available for the formation of highly homogeneous ADCs, disulfide modification is considered an effective, low-cost, and widely accepted method for modifying IgG1s for improved clinical benefit. However, little is known about how disulfide modification impacts clinically relevant fragment crystallizable (Fc) region interactions. Although often overlooked as a secondary ADC function, Fc interactions could prove key in the rational design of cancer cell-targeting ADCs through consideration of potent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC). This work explores different IgG1 disulfide modification techniques and the effect they have on quantifiable secondary IgG1 Fc interactions (e.g., CD16a and FcRn). The solvent accessible disulfide residues of trastuzumab, a clinically relevant IgG1, were modified to provide a range of bioconjugates with differing amounts of interchain covalent linkages. It was found that by natively rebridging the IgG1 model, all tested Fc functionalities were not significantly affected. Additionally, in non Fc-specific biophysical experiments (e.g., thermal stability/aggregation), the natively rebridged species provided an exceptional profile, showing no significant change from the tested native antibody. Conjugates with significant disruption of the covalent connectivity of IgG1 chains resulted in a suboptimal Fc profile (CD16a kinetics or ADCC activity), in addition to substandard non Fc-specific attributes (thermal stability). These results advocate native disulfide rebridging as an excellent synthetic strategy for forming homogeneous IgG1 bioconjugates, with no reported negative impact on biophysical profile relative to the native antibody.
Collapse
Affiliation(s)
- Calise Bahou
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom.,LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - Elizabeth A Love
- LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - Siobhán Leonard
- LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - Richard J Spears
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom
| | - Antoine Maruani
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom
| | - Kathryn Armour
- LifeArc , Accelerator Building, SBC Open Innovation Campus, SG1 2FX , Stevenage , United Kingdom
| | - James R Baker
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom
| | - Vijay Chudasama
- Department of Chemistry , University College London , 20 Gordon Street , WC1H OAJ , London , United Kingdom.,Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy , Universidade de Lisboa , 1649-004 Lisbon , Portugal
| |
Collapse
|
40
|
Sandland J, Boyle RW. Photosensitizer Antibody–Drug Conjugates: Past, Present, and Future. Bioconjug Chem 2019; 30:975-993. [DOI: 10.1021/acs.bioconjchem.9b00055] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
41
|
Robertson NS, Walsh SJ, Fowler E, Yoshida M, Rowe SM, Wu Y, Sore HF, Parker JS, Spring DR. Macrocyclisation and functionalisation of unprotected peptides via divinyltriazine cysteine stapling. Chem Commun (Camb) 2019; 55:9499-9502. [PMID: 31328756 DOI: 10.1039/c9cc05042f] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
We report a novel divinyltriazine linker for the stapling of two cysteine residues to form macrocyclic peptides from their unprotected linear counterparts. The stapling reaction occurred rapidly under mild conditions on a range of unprotected peptide sequences. The resulting constrained peptides displayed greater stability in a serum stability assay when compared to their linear counterparts.
Collapse
Affiliation(s)
- Naomi S Robertson
- Department of Chemistry, University of Cambridge, Lensfield Rd, Cambridge, CB2 1EW, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Morais M, Forte N, Chudasama V, Baker JR. Application of Next-Generation Maleimides (NGMs) to Site-Selective Antibody Conjugation. Methods Mol Biol 2019; 2033:15-24. [PMID: 31332744 DOI: 10.1007/978-1-4939-9654-4_2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Site-selective antibody conjugation is widely recognized as a key strategy for the optimum construction of antibody-drug conjugates (ADCs). Achieving such bioconjugation directly onto native antibodies would represent the ideal solution, as it would afford greatly improved homogeneity whilst avoiding the need for genetic engineering, and even allow the repurposing of existing antibodies "off-the shelf." Here we describe a protocol for the use of next-generation maleimides (NGMs) for the selective modification of the four interchain disulfide bonds present in a typical IgG1 antibody format. These reagents retain the efficiency of classical maleimides whilst serving to rebridge each reduced disulfide bond, affording one attachment per disulfide. The approach is simple, uses readily available reagents, and generates robustly stable conjugates which are ideal for in vitro or in vivo applications. In addition to use in the construction of ADCs these reagents can also be used to develop antibody conjugates for imaging, bispecifics, and broadly for use across biology and medicine.
Collapse
Affiliation(s)
- Maurício Morais
- Department of Chemistry, University College London, London, UK
| | - Nafsika Forte
- Department of Chemistry, University College London, London, UK
| | - Vijay Chudasama
- Department of Chemistry, University College London, London, UK
| | - James R Baker
- Department of Chemistry, University College London, London, UK.
| |
Collapse
|
43
|
van Berkel SS, van Delft FL. Enzymatic strategies for (near) clinical development of antibody-drug conjugates. DRUG DISCOVERY TODAY. TECHNOLOGIES 2018; 30:3-10. [PMID: 30553518 DOI: 10.1016/j.ddtec.2018.09.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 09/21/2018] [Accepted: 09/22/2018] [Indexed: 05/20/2023]
Abstract
Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. At present, various (chemo)enzymatic approaches for site-specific and stable conjugation of toxic payloads are making their way to the clinic, thereby potentially providing ADCs with increased therapeutic window.
Collapse
Affiliation(s)
| | - Floris L van Delft
- Synaffix BV, Kloosterstraat 9, 5349 AB, Oss, The Netherlands; Wageningen University and Research, Laboratory of Organic Chemistry, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
| |
Collapse
|
44
|
Forte N, Chudasama V, Baker JR. Homogeneous antibody-drug conjugates via site-selective disulfide bridging. DRUG DISCOVERY TODAY. TECHNOLOGIES 2018; 30:11-20. [PMID: 30553515 DOI: 10.1016/j.ddtec.2018.09.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Accepted: 09/19/2018] [Indexed: 06/09/2023]
Abstract
Antibody-drug conjugates (ADCs) constructed using site-selective labelling methodologies are likely to dominate the next generation of these targeted therapeutics. To this end, disulfide bridging has emerged as a leading strategy as it allows the production of highly homogeneous ADCs without the need for antibody engineering. It consists of targeting reduced interchain disulfide bonds with reagents which reconnect the resultant pairs of cysteine residues, whilst simultaneously attaching drugs. The 3 main reagent classes which have been exemplified for the construction of ADCs by disulfide bridging will be discussed in this review; bissulfones, next generation maleimides and pyridazinediones, along with others in development.
Collapse
Affiliation(s)
- Nafsika Forte
- Department of Chemistry, University College London, London, UK
| | - Vijay Chudasama
- Department of Chemistry, University College London, London, UK.
| | - James R Baker
- Department of Chemistry, University College London, London, UK.
| |
Collapse
|
45
|
Szijj PA, Bahou C, Chudasama V. Minireview: Addressing the retro-Michael instability of maleimide bioconjugates. DRUG DISCOVERY TODAY. TECHNOLOGIES 2018; 30:27-34. [PMID: 30553517 DOI: 10.1016/j.ddtec.2018.07.002] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 06/25/2018] [Accepted: 07/12/2018] [Indexed: 05/17/2023]
Abstract
Bioconjugation, the modification of biological macromolecules such as proteins, is an up and coming area in the field of chemical biology. Antibody-drug conjugates (ADCs), combining the antigen-selectivity of natural antibodies with the cytotoxic potency of small molecule drugs, are a powerful therapeutic technology. Four such constructs are currently on the market for cancer therapy. However, the conjugation methodology employed in these therapeutics is far from ideal. Herein we provide an overview on methods that attempt to increase the safety and efficacy of ADCs via "self-hydrolysing maleimides" or by improving the stability of maleimide-conjugates by other means. We find that some very promising reagents have been reported, however the mechanism by which each of these reagents acts is not clear, thus limiting rational design for some strategies.
Collapse
Affiliation(s)
- Peter A Szijj
- Department of Chemistry, University College London, London, UK
| | - Calise Bahou
- Department of Chemistry, University College London, London, UK
| | - Vijay Chudasama
- Department of Chemistry, University College London, London, UK.
| |
Collapse
|
46
|
Richards DA. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. DRUG DISCOVERY TODAY. TECHNOLOGIES 2018; 30:35-46. [PMID: 30553519 DOI: 10.1016/j.ddtec.2018.10.005] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Revised: 10/12/2018] [Accepted: 10/15/2018] [Indexed: 05/20/2023]
Abstract
The field of targeted therapeutics has benefitted immeasurably from the development of high-affinity antibodies. These important ligands have facilitated the development of effective therapies, particularly when conjugated to potent cytotoxic payloads i.e. in antibody-drug conjugates (ADCs). The success of ADCs is evidenced by rapid adoption within the pharmaceuticals community; many major companies have dedicated ADC research programmes. However, despite the advantages, the field of ADCs has failed to live up to its full potential. Studies have emerged suggesting that traditional IgG scaffolds may not be the optimal format for targeted payload delivery. In response, the protein engineering community has begun to explore alternative high-binding protein scaffolds as antibody mimics. In this short review I will summarise the generation, modification, and application of emerging antibody fragments and synthetic antibody mimics, with a focus on their use as drug carriers. The review aims to highlight the advantages of antibody mimics, and how they could be employed to overcome the issues and limitations of traditional ADCs.
Collapse
Affiliation(s)
- Daniel A Richards
- Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK.
| |
Collapse
|
47
|
Zegota MM, Wang T, Seidler C, Wah Ng DY, Kuan SL, Weil T. "Tag and Modify" Protein Conjugation with Dynamic Covalent Chemistry. Bioconjug Chem 2018; 29:2665-2670. [PMID: 29949347 DOI: 10.1021/acs.bioconjchem.8b00358] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The development of small protein tags that exhibit bioorthogonality, bond stability, and reversibility, as well as biocompatibility, holds great promise for applications in cellular environments enabling controlled drug delivery or for the construction of dynamic protein complexes in biological environments. Herein, we report the first application of dynamic covalent chemistry both for purification and for reversible assembly of protein conjugates using interactions of boronic acid with diols and salicylhydroxamates. Incorporation of the boronic acid (BA) tag was performed in a site-selective fashion by applying disulfide rebridging strategy. As an example, a model protein enzyme (lysozyme) was modified with the BA tag and purified using carbohydrate-based column chromatography. Subsequent dynamic covalent "click-like" bioconjugation with a salicylhydroxamate modified fluorescent dye (BODIPY FL) was accomplished while retaining its original enzymatic activity.
Collapse
Affiliation(s)
- Maksymilian Marek Zegota
- Max-Planck Institute for Polymer Research , Ackermannweg 10 , 55128 Mainz , Germany.,Institute of Inorganic Chemistry I , University of Ulm , Albert-Einstein-Allee 11 , 89081 Ulm , Germany
| | - Tao Wang
- Institute of Inorganic Chemistry I , University of Ulm , Albert-Einstein-Allee 11 , 89081 Ulm , Germany.,School of Materials Science and Engineering , Southwest Jiaotong University , 610031 Chengdu , P.R. China
| | - Christiane Seidler
- Max-Planck Institute for Polymer Research , Ackermannweg 10 , 55128 Mainz , Germany.,Institute of Inorganic Chemistry I , University of Ulm , Albert-Einstein-Allee 11 , 89081 Ulm , Germany
| | - David Yuen Wah Ng
- Max-Planck Institute for Polymer Research , Ackermannweg 10 , 55128 Mainz , Germany.,Institute of Inorganic Chemistry I , University of Ulm , Albert-Einstein-Allee 11 , 89081 Ulm , Germany
| | - Seah Ling Kuan
- Max-Planck Institute for Polymer Research , Ackermannweg 10 , 55128 Mainz , Germany.,Institute of Inorganic Chemistry I , University of Ulm , Albert-Einstein-Allee 11 , 89081 Ulm , Germany
| | - Tanja Weil
- Max-Planck Institute for Polymer Research , Ackermannweg 10 , 55128 Mainz , Germany.,Institute of Inorganic Chemistry I , University of Ulm , Albert-Einstein-Allee 11 , 89081 Ulm , Germany
| |
Collapse
|
48
|
Shao S, Tsai MH, Lu J, Yu T, Jin J, Xiao D, Jiang H, Han M, Wang M, Wang J. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett 2018; 28:1363-1370. [DOI: 10.1016/j.bmcl.2018.03.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 02/28/2018] [Accepted: 03/02/2018] [Indexed: 01/19/2023]
|
49
|
Koniev O, Dovgan I, Renoux B, Ehkirch A, Eberova J, Cianférani S, Kolodych S, Papot S, Wagner A. Reduction-rebridging strategy for the preparation of ADPN-based antibody-drug conjugates. MEDCHEMCOMM 2018; 9:827-830. [PMID: 30108971 DOI: 10.1039/c8md00141c] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 04/07/2018] [Indexed: 02/02/2023]
Abstract
The reduction-rebridging strategy is a powerful method for the preparation of stable and homogeneous antibody-drug conjugates (ADCs). In this communication, we describe the development of the arylene-dipropiolonitrile (ADPN) functional group for the rebridging of reduced disulphide bonds and its application in the preparation of potent and selective ADCs.
Collapse
Affiliation(s)
- Oleksandr Koniev
- Syndivia SAS , 650 Bd Gonthier d'Andernach , 67400 Illkirch , France .
| | - Igor Dovgan
- Laboratory of Functional ChemoSystems (UMR 7199) , Labex Medalis , University of Strasbourg , 74 route du Rhin , 67401 Illkirch-Graffenstaden , France
| | - Brigitte Renoux
- Institut de Chimie des Milieux et des Matériaux de Poitiers , IC2MP , Université de Poitiers , UMR-CNRS 7285, 4 Rue Michel Brunet , 86022 Poitiers , France
| | - Anthony Ehkirch
- BioOrganic Mass Spectrometry Laboratory (LSMBO) , IPHC , Université de Strasbourg , 25 rue Becquerel , 67087 Strasbourg , France.,IPHC , CNRS , UMR7178 , 67087 Strasbourg , France
| | - Jitka Eberova
- Laboratory of Functional ChemoSystems (UMR 7199) , Labex Medalis , University of Strasbourg , 74 route du Rhin , 67401 Illkirch-Graffenstaden , France
| | - Sarah Cianférani
- BioOrganic Mass Spectrometry Laboratory (LSMBO) , IPHC , Université de Strasbourg , 25 rue Becquerel , 67087 Strasbourg , France.,IPHC , CNRS , UMR7178 , 67087 Strasbourg , France
| | - Sergii Kolodych
- Syndivia SAS , 650 Bd Gonthier d'Andernach , 67400 Illkirch , France .
| | - Sébastien Papot
- Institut de Chimie des Milieux et des Matériaux de Poitiers , IC2MP , Université de Poitiers , UMR-CNRS 7285, 4 Rue Michel Brunet , 86022 Poitiers , France
| | - Alain Wagner
- Laboratory of Functional ChemoSystems (UMR 7199) , Labex Medalis , University of Strasbourg , 74 route du Rhin , 67401 Illkirch-Graffenstaden , France
| |
Collapse
|
50
|
Forte N, Livanos M, Miranda E, Morais M, Yang X, Rajkumar VS, Chester KA, Chudasama V, Baker JR. Tuning the Hydrolytic Stability of Next Generation Maleimide Cross-Linkers Enables Access to Albumin-Antibody Fragment Conjugates and tri-scFvs. Bioconjug Chem 2018; 29:486-492. [PMID: 29384367 DOI: 10.1021/acs.bioconjchem.7b00795] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We describe investigations to expand the scope of next generation maleimide cross-linkers for the construction of homogeneous protein-protein conjugates. Diiodomaleimides are shown to offer the ideal properties of rapid bioconjugation with reduced hydrolysis, allowing the cross-linking of even sterically hindered systems. The optimized linkers are exploited to link human serum albumin to antibody fragments (Fab or scFv) as a prospective half-life extension platform, with retention of antigen binding and robust serum stability. Finally, a triprotein conjugate is formed, by linking scFv antibody fragments targeting carcinoembryonic antigen. This tri-scFv is shown to infer a combination of greater antigen avidity and increased in vivo half-life, representing a promising platform for antibody therapeutic development.
Collapse
Affiliation(s)
- Nafsika Forte
- Department of Chemistry, University College London , 20 Gordon Street, London, WC1H OAJ, United Kingdom
| | - Maria Livanos
- Cancer Institute, University College London , 72 Huntley Street, London, WC1E 6BT, United Kingdom
| | - Enrique Miranda
- Cancer Institute, University College London , 72 Huntley Street, London, WC1E 6BT, United Kingdom
| | - Maurício Morais
- Department of Chemistry, University College London , 20 Gordon Street, London, WC1H OAJ, United Kingdom
| | - Xiaoping Yang
- Department of Chemistry, University College London , 20 Gordon Street, London, WC1H OAJ, United Kingdom
| | - Vineeth S Rajkumar
- Cancer Institute, University College London , 72 Huntley Street, London, WC1E 6BT, United Kingdom
| | - Kerry A Chester
- Cancer Institute, University College London , 72 Huntley Street, London, WC1E 6BT, United Kingdom
| | - Vijay Chudasama
- Department of Chemistry, University College London , 20 Gordon Street, London, WC1H OAJ, United Kingdom.,Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa , 1649-004 Lisbon, Portugal
| | - James R Baker
- Department of Chemistry, University College London , 20 Gordon Street, London, WC1H OAJ, United Kingdom
| |
Collapse
|